Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03384836
Other study ID # I 53217
Secondary ID NCI-2017-02210I
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 31, 2018
Est. completion date January 31, 2025

Study information

Verified date November 2023
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase Ib/II trial studies the side effects and best dose of propranolol hydrochloride when given together with pembrolizumab and how well they work in treating patients with stage IIIC-IV melanoma that cannot be removed by surgery. Pembrolizumab is a monoclonal antibody that "takes the brakes off the immune system" and thus allows for anti-tumor immune responses. Propranolol hydrochloride is a beta adrenergic blocking agent that can enhance immune cell responses when under stress. Giving propranolol hydrochloride and pembrolizumab may work better in treating patients with melanoma.


Description:

PRIMARY OBJECTIVES: I. To determine dose limiting toxicities (DLT) of propranolol hydrochloride (propranolol) in combination with fixed dose pembrolizumab in the treatment of melanoma. II. To evaluate the efficacy of pembrolizumab in combination with propranolol in patients with melanoma, as determined by overall response rate (ORR) per immune-modified Response Evaluation Criteria in Solid Tumors (RECIST) (1). SECONDARY OBJECTIVES: I. To evaluate the efficacy of pembrolizumab in combination with propranolol in patients with melanoma, as determined by secondary measures of efficacy, including: progression free survival (PFS) and overall survival (OS). TERTIARY OBJECTIVES: I. To correlate baseline or changes in the levels of biomarkers, like, peripheral T-cell subsets/myeloid derived suppressor cells (MDSC)/cytokines/urinary catecholamine and perceived stress scale (PSS) with efficacy (ORR, PFS, OS) in melanoma patients treated with pembrolizumab and propranolol. OUTLINE: This is a phase Ib, dose-escalation study of propranolol hydrochloride followed by a phase II study. Patients receive propranolol hydrochloride orally (PO) twice daily (BID) and pembrolizumab intravenously (IV) over 30 minutes of day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, every 3 months for 6 months, and then every 6 months thereafter.


Recruitment information / eligibility

Status Recruiting
Enrollment 47
Est. completion date January 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma - Have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Available archival formalin-fixed paraffin-embedded (FFPE) from a prior biopsy or, participant must be willing to have a tissue biopsy taken at a clinic visit prior to start of study treatment - Have measurable disease per irRECIST v1.1 - Ability to swallow and retain oral medication - Absolute neutrophil count (ANC) >= 1500/uL - Hemoglobin (Hb) >= 9 g/dL - Platelet count >= 100, 000/uL - Total bilirubin =< 1.5 x ULN (upper limit of normal) - unless patient has Gilbert's syndrome - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN - If the patient has liver metastasis AST and ALT less than or greater to 5x ULN - Serum or plasma (based on site's SOP) creatinine < 2 x ULN - Participants of child-bearing potential must have a negative pregnancy test at study entry and then agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately - Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: - Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors - Participants with chronic autoimmune diseases - Participants that are already on non-selective B-AR blockers for various indications. Patients on selective beta-blockers are considered eligible for enrollment with a caveat that their clinician prescribing the beta-blocker is willing to discontinue their selective beta-blocker in order to transition to propranolol at the specified protocol dose. - Participants with symptomatic known brain metastases < 4 weeks from radiation treatment should be excluded from this clinical trial - Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer >=3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant or nursing female participants, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test - Unwilling or unable to follow protocol requirements - Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug - Other active non-melanoma metastatic cancers - Contraindications to the use of beta-blockers, like, uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (grade III or IV), hypotension (systolic blood pressure < 100 mmHg), bradycardia (resting heart rate <55bpm), severe asthma or chronic obstructive pulmonary disease (COPD), uncontrolled type I or type II diabetes mellitus (glycosylated hemoglobin [HbA1C] > 8.5 or fasting plasma glucose > 160 mg/dl at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current use or past use in the last two years of non-selective beta-blockers or non-dihydropyridine calcium channel blockers. Patients on selective beta blockers will be eligible for enrollment only under the condition that their prescribing clinician is willing to discontinue their selective beta blocker in order to begin propranolol and only at the specified dose (after which time the patient is not to be started on any non-selective beta-blockers or non-dihydropyridine calcium channel blockers) - Patient is currently receiving or has received systemic corticosteroids (=< 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment) - Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of the study drug - Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Administration of killed vaccines is allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Biological:
Pembrolizumab
Given IV
Drug:
Propranolol Hydrochloride
Given PO

Locations

Country Name City State
United States Emory University Hospital/ Winship Cancer Institute Atlanta Georgia
United States Roswell Park Cancer Institute Buffalo New York
United States Cleveland Clinic Cancer Center Cleveland Ohio
United States Penn State Milton S. Hershy Medical Center Cancer Institute Hershey Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in the levels of biomarkers to correlate baseline or changes in levels of biomarkers with efficacy in melanoma patients treated with pembrolizumab and propranolol. Baseline up to 2 years
Primary Dose limiting toxicities (DLT) defined as any grade 3 or higher hematological or non-hematological toxicity that is probably or definitely related to treatment according to Common Terminology Criteria for Adverse Events version 4.03 (Phase Ib) Adverse events and toxicities will be summarized by dose level using frequencies and relative frequencies. Up to 12 weeks
Primary Overall response rate (ORR) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) version 1.1 (Phase II) ORR is defined as partial or complete response within 6 months of initiating combination therapy. Up to 6 months
Secondary Overall survival (OS) (Phase II) Will be summarized using standard Kaplan-Meier methods and rates will be obtained with 90% confidence intervals. From treatment initiation until death due to any cause (event) or last follow-up, assessed up to 2 years
Secondary PFS (Phase II) Will summarized using standard Kaplan-Meier methods and rates will be obtained with 90% confidence intervals. From treatment initiation until disease progression, death due to disease (events), or last follow-up, assessed up to 2 years
Secondary Progression free survival (PFS) (Phase II) Will be summarized using standard Kaplan-Meier methods and rates will be obtained with 90% confidence intervals. At 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02196181 - Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Phase 2
Completed NCT02158520 - Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT01955460 - Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma Phase 1
Recruiting NCT02339571 - A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Phase 2/Phase 3
Active, not recruiting NCT01480154 - Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Phase 1
Active, not recruiting NCT03325101 - Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery Phase 1/Phase 2
Active, not recruiting NCT02097225 - Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Active, not recruiting NCT01274338 - Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Phase 3
Active, not recruiting NCT01364051 - Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Phase 1
Completed NCT02304458 - Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Phase 1/Phase 2
Terminated NCT03050060 - Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Phase 2
Active, not recruiting NCT02965716 - Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Phase 2
Active, not recruiting NCT01590069 - Aerosolized Aldesleukin in Treating Patients With Lung Metastases Phase 1
Terminated NCT03425461 - Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma Phase 1
Active, not recruiting NCT01638533 - Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase 1
Active, not recruiting NCT01902173 - Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Phase 1/Phase 2
Active, not recruiting NCT00937937 - Dinaciclib in Treating Patients With Stage IV Melanoma Phase 2
Active, not recruiting NCT03021460 - Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Phase 1
Completed NCT01740557 - Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma Phase 1/Phase 2
Active, not recruiting NCT01950390 - Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Phase 2